On Jannuary 6, 2021, Moderna’s COVID-19 mRNA vaccine received Conditional Marketing Approval (CMA) by the European Medicines Agency (EMA), meeting their criteria, stating after clinical trial evidence showed efficacy (94·1%) and safety. This is the second CMA, following Pfizer. [1, 2, 3]
